|
1
|
Pritchard RS and Anthony SP: Chemotherapy
plus radiotherapy compared with radiotherapy alone in the treatment
of locally advanced, unresectable, non-small-cell lung cancer. A
mata-anaysis. Ann Intern Med. 125:723–729. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marino P, Preatoni A and Cantoni A:
Randomized trials of radiotherapy alone versus combined
chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell
lung cancer. A meta-analysis. Cancer. 76:593–601. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et
al: Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC. N Engl J Med. 379:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naito Y, Kubota K, Nihei K, Fujii T, Yoh
K, Niho S, Goto K, Ohmatsu H, Saijo N and Nishiwaki Y: Concurrent
chemoradiotherapy with cisplatin and vinorelbine for stage III
Non-small cell lung cancer. J Thorac Oncol. 3:617–622. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnson ML, Cho BC, Luft A,
Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G,
Hussein M, Lim FL, et al: Durvalumab with or without tremelimumab
in combination with chemotherapy as first-line therapy for
metastatic non-small-cell lung cancer: The phase III POSEIDON
study. J Clin Oncol. 41:1213–1227. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamamoto N, Nakagawa K, Nishimura Y,
Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K,
Katakami N, et al: Phase III study comparing second- and
third-generation regimens with concurrent thoracic radiotherapy in
patients with unresectable stage III non-small-cell lung cancer:
West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol.
28:3739–3745. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sasaki T, Seto T, Yamanaka T, Kunitake N,
Shimizu J, Kodaira T, Nishio M, Kozuka T, Takahashi T, Harada H, et
al: A randomised phase II trial of S-1 plus cisplatin versus
vinorelbine plus cisplatin with concurrent thoracic radiotherapy
for unresectable, locally advanced non-small cell lung cancer:
WJOG5008L. Br J Cancer. 119:675–682. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shukuya T, Takahashi T, Harada H, Akamatsu
H, Sakaguchi C, Imai H, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, et
al: Comparison of vinorelbine plus cisplatin and s-1 plus cisplatin
in concurrent chemoradiotherapeutic regimens for unresectable stage
III Non-small Cell lung cancer. Anticancer Res. 32:675–680.
2012.PubMed/NCBI
|
|
10
|
Scagliotti GV, Parikh P, Von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rogers SJ, Lomax N, Alonso S, Lazeroms T
and Riesterer O: Radiosurgery for five to fifteen brain metastases:
A single centre experience and a review of the literature. Front
Oncol. 12:8665422022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dewan MC, Rattani A, Fieggen G, Arraez MA,
Servadei F, Boop FA, Johnson WD, Warf BC and Park KB: Global
neurosurgery: The current capacity and deficit in the provision of
essential neurosurgical care. Executive summary of the global
neurosurgery initiative at the program in global surgery and social
change. J Neurosurg. 130:1055–1064. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spigel DR, Faivre-Finn C, Gray JE, Vicente
D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R,
Quantin X, et al: Five-year survival outcomes from the PACIFIC
trial: Durvalumab after chemoradiotherapy in stage III
non-small-cell lung cancer. J Clin Oncol. 40:1301–1311. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hasegawa T, Ariyasu R, Tanaka H, Saito R,
Kawashima Y, Horiike A, Sakatani T, Tozuka T, Shiihara J, Saiki M,
et al: Subsequent treatment for locally advanced non-small-cell
lung cancer that progressed after definitive chemoradiotherapy and
consolidation therapy with durvalumab: A multicenter retrospective
analysis (TOPGAN 2021-02). Cancer Chemother Pharmacol. 92:29–37.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pires da Silva I, Ahmed T, Reijers ILM,
Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous
C, Mangana J, Nguyen K, et al: Ipilimumab alone or ipilimumab plus
anti-PD-1 therapy in patients with metastatic melanoma resistant to
anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort
study. Lancet Oncol. 22:836–847. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schoenfeld JD, Giobbie-Hurder A,
Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler
RD, Lee C, et al: Durvalumab plus tremelimumab alone or in
combination with low-dose or hypofractionated radiotherapy in
metastatic non-small-cell lung cancer refractory to previous
PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2
trial. Lancet Oncol. 23:279–291. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker
M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E,
Juan-Vidal O, et al: First-line nivolumab plus ipilimumab combined
with two cycles of chemotherapy in patients with non-small-cell
lung cancer (CheckMate 9LA): An international, randomised,
open-label, phase 3 trial. Lancet Oncol. 22:198–211. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lau B, No HJ, Wu YF, Ko RB, Devine M, Das
M, Neal JW, Wakelee HA, Ramchandran KJ, Wakelee HA, et al:
Pulmonary hemorrhage in patients treated with thoracic stereotactic
ablative radiotherapy and anti-angiogenic agents. Int J Radiat
Oncol Biol Phys. 111:e4232021. View Article : Google Scholar
|
